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Vaccine Development
Discovery
• Immunopathogenesis
• Ag & biomarker 
discovery
Preclinical 
studies
• Animal studies
• GLP tox
Clinical
development
• Phase 1 & 2, US 
& Mali
• Proof of concept
Vaccine
production
• Protein production
• Conjugation
• Formulation
• QA/QC
LMIV Mission
• Pre-erythrocytic vaccine
• Transmission Blocking Vaccine
• Pregnancy malaria vaccine
• Merozoite vaccine
Current aims
Waters, Cell 2006,124:689
• Pfs25
− Ookinete surface protein
− Produced in P. pastoris
− ± HIS6 fusion tag
• Pvs25
• Bio-assay: Membrane feeding
Clinical development, TBV
• CSP
− Sporozoite surface protein
− Produced in Pichia pastoris 
and in E. coli
Pre-clinical development, 
pre-erythrocytic vaccine
TBV: Pfs25 is a Lead Candidate
• Recombinant Pfs25 (& Pvs25) 
consistently induces functional 
antisera assessed by 
membrane feeding assay
• TB activity observed using 
purified IgG, with or without 
complement
• Human serum antibodies 
against Pfs25 demonstrate TB 
activity 
• Development goal: enhance 
immunogenicity and longevity:
– Conjugation
– Adjuvants
• BALB/c mice
• Swiss outbred mice
• Immunized protein on Alum IM on D0 & D28
• Abs measured on D42
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Transmission Blocking Activity 
in Mouse Sera
Pfs25 Pfs25-EPA
% Inhibition of oocyst 
count
55.7 99.3 
% Inhibition of 
prevalence
12% 90%
Membrane feeding assay
Goal is zero oocysts; percent inhibition is assay correlate
Pilot-scale conjugation process
Pfs25-SH: ~3 linkers
EPA-EMCS: ~7 linkers
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Pfs25-EPA characterization
In process and bulk
• Appearance
• AAA
• Absorbance 280 nm
• AFM
• BCA
• Coomassie blue stained 
– SDS-PAGE
– SDS-agarose_GE
• Endotoxin
• Trp fluorescence
• General safety
• HCP
• Linker addition
• pH
• RP-HPLC
• SEC-MALS-HPLC
• Sterility
• Western blot
In-house reference: MV1351 cGMP lot
Comparison of Bulk Pfs25-EPA 
Conjugates
Reverse-phase HPLC analysis
cGMP lot, Mw = 545 kDa, Rh= 12.3 nm
In-house reference (MV1351), Mw = 558 kDa, Rh= 12.4 nm
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Comparison of Pfs25-EPA conjugates by 
SEC-MALS-QELS-HPLC
• Pfs25-EPA MV1351
• Conditions:
− Deposition 10 min.
on clean mica in 
PBS
Analysis of Pfs25-EPA conjugate by AFM
Clinical development path for TBVs
Phase 1 
US adults 
Safe
High TB Abs
Sustained TB Abs
Phase 1 malaria 
exposed adults 
Phase 1 malaria 
exposed children
Phase 2b Proof of 
Concept
Additional 
antigens/ 
reformulation
Safe
High TB Abs
Sustained TB Abs
Safe
High TB Abs
Sustained TB Abs
Approaches to Improve TBV Efficacy
• Combine with other target antigen(s)
– CSP (pre-erythrocytic)
– Pfs230 (TBV)
– Novel antigens (pre-erythrocytic and/or TBV)
• Other carriers
– CRM197
– Qbeta
– OMPC
CSP Pre-erythrocytic Vaccine
• Identify suitable CS protein construct
– No HIS tag
– Scalable process
– Compatible with conjugation strategies
• Two forms of recombinant CSP produced
– AN87606 (India Strain)
• E. coli full length without signal sequence and GPI anchor 
plus HIS6 tag
• P. pastoris near full-length with and without free thiol
– NP473175 (3D7)
• P. pastoris near full-length with and without free thiol
TSR
REPEAT
N-term
±SH
Pre-erythrocytic vaccine development
recombinant P. pastoris CSP
Plassmeyer et al., 2009 JBC 284:26951 
Recombinant PpCSP
1 x 25-30 nm
Region I
Coomassie blue stained SDS-PAGE gels
PpCSP M2 PpCSP M2C
NRNR R R
1 5 1 5 1 5 1 5 µg
Enhanced CSP immunogenicity:
CRM197 conjugate, GLA/SE adjuvant
Mice immunized on D0 and D28
Summary
• cGMP pilot-scale production of Pfs25-EPA 
successful
• Analytical parameters qualified for testing of bulk 
substance
• Formulation development for Pfs25-EPA 
ongoing
• Human phase 1 trial planned for 1qtr 2011
• Pre-clinical studies ongoing for enhancing TBV 
efficacy
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